Brief: Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data For XTX101
09/08/2022 12:31
Aug 9 (Reuters) - Xilio Therapeutics Inc XLO.O :
* XILIO THERAPEUTICS ANNOUNCES ENCOURAGING PRELIMINARY PHASE 1
DOSE-ESCALATION
DATA FOR XTX101, A TUMOR-SELECTIVE ANTI-CTLA-4, AND REPORTS PIPELINE AND
BUSINESS UPDATES AND SECOND QUARTER 2022 FINANCIAL RESULTS
* XILIO THERAPEUTICS INC - XTX202, TUMOR-SELECTIVE IL-2, ADVANCING IN
DOSE-ESCALATION OF PHASE 1 CLINICAL TRIAL
* XILIO THERAPEUTICS INC - INVESTIGATIONAL NEW DRUG APPLICATION PLANNED FOR
XTX301, TUMOR SELECTIVE IL-12, IN Q4 OF 2022
Source text for Eikon: ID:nGNXbRSWmd
Further company coverage: XLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla